ES2583804T3 - Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno - Google Patents

Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno Download PDF

Info

Publication number
ES2583804T3
ES2583804T3 ES08837079.6T ES08837079T ES2583804T3 ES 2583804 T3 ES2583804 T3 ES 2583804T3 ES 08837079 T ES08837079 T ES 08837079T ES 2583804 T3 ES2583804 T3 ES 2583804T3
Authority
ES
Spain
Prior art keywords
solution
dantrolene
lyophilization
pharmaceutical
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08837079.6T
Other languages
English (en)
Spanish (es)
Inventor
Ahmad Malkawi
Abeer M. Al-Ghananeem
Patrick Deluca
George A. Digenis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US WORLDMEDS LLC
Original Assignee
US WORLDMEDS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US WORLDMEDS LLC filed Critical US WORLDMEDS LLC
Application granted granted Critical
Publication of ES2583804T3 publication Critical patent/ES2583804T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES08837079.6T 2007-10-09 2008-09-05 Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno Active ES2583804T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97862607P 2007-10-09 2007-10-09
US978626P 2007-10-09
PCT/US2008/075406 WO2009048698A1 (en) 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Publications (1)

Publication Number Publication Date
ES2583804T3 true ES2583804T3 (es) 2016-09-22

Family

ID=40316940

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08837079.6T Active ES2583804T3 (es) 2007-10-09 2008-09-05 Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno

Country Status (6)

Country Link
US (1) US8975284B2 (cg-RX-API-DMAC7.html)
EP (2) EP2583670A1 (cg-RX-API-DMAC7.html)
JP (1) JP5406197B2 (cg-RX-API-DMAC7.html)
CA (1) CA2702243C (cg-RX-API-DMAC7.html)
ES (1) ES2583804T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009048698A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042408A2 (en) * 2006-10-03 2008-04-10 Wyeth Lyophilization methods and apparatuses
WO2009067175A2 (en) 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Oligomer-dantrolene conjugates and related compounds
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene
US20140072525A1 (en) * 2012-09-07 2014-03-13 Gaab, Llc Antimicrobial preparation and methods for making and using the same
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
EP2968229B1 (en) * 2013-03-15 2019-12-04 Rosalind Franklin University of Medicine and Science Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof
JP7409772B2 (ja) 2015-10-20 2024-01-09 スぺファーム アクチェンゲゼルシャフト ダントロレンを含む水性組成物
US20200230126A1 (en) * 2017-06-20 2020-07-23 Tarveda Therapeutics, Inc. Targeted therapeutics
MY201417A (en) * 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
EP3773488A4 (en) * 2018-04-05 2021-11-17 Tarveda Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AT REDUCED TERT-BUTANOL LEVELS
JPWO2020049670A1 (ja) * 2018-09-06 2021-08-12 シミックホールディングス株式会社 ダントロレン水性製剤及びその調製方法
US12246028B2 (en) * 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
WO2022169582A1 (en) * 2021-02-05 2022-08-11 Uswm, Llc Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4543359A (en) 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
US5149621A (en) 1987-08-21 1992-09-22 Cryolife, Inc. & Medical Univ. Of South Carolina Kit for cryopreserving blood vessels
US5158867A (en) 1987-08-21 1992-10-27 Cryolife Inc. Method for cryopreserving blood vessels
US5145769A (en) 1987-08-21 1992-09-08 Cryolife Inc. Method for cryopreserving blood vessels
JPH01128923A (ja) * 1987-11-11 1989-05-22 Mikasa Seiyaku Kk 骨格筋弛緩外用剤
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
AU5015193A (en) * 1992-09-09 1994-03-29 Washington University Prevention or treatment of sepsis with dantrolene or azumolene
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
WO1995028914A1 (en) 1994-04-21 1995-11-02 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
US5597809A (en) 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US20030045587A1 (en) * 2001-06-23 2003-03-06 David Anderson Solvent system
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2005013919A2 (en) * 2003-03-04 2005-02-17 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina

Also Published As

Publication number Publication date
US20110015243A2 (en) 2011-01-20
US8975284B2 (en) 2015-03-10
WO2009048698A1 (en) 2009-04-16
EP2583670A1 (en) 2013-04-24
US20090093531A1 (en) 2009-04-09
EP2219605B1 (en) 2015-08-19
WO2009048698A9 (en) 2009-11-19
WO2009048698A4 (en) 2013-05-30
JP2011500570A (ja) 2011-01-06
CA2702243C (en) 2016-06-21
JP5406197B2 (ja) 2014-02-05
CA2702243A1 (en) 2009-04-16
EP2219605A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
ES2583804T3 (es) Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno
US20110160261A2 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
EP2094308B1 (en) Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
JP6542888B2 (ja) カルムスチン医薬組成物
KR102459213B1 (ko) 카르글룸산을 함유하는 약제학적 비경구 제형
EP3007681A1 (en) Stable and water soluble pharmaceutical compositions comprising pemetrexed
KR0164845B1 (ko) 동결-건조된 헤마토포르피린 조성물 및 이의 제조방법
ES2946600T3 (es) Formulaciones líquidas de daptomicina
EP3008064B1 (en) Stable pemetrexed arginine salt and compositions comprising it
US20120283304A1 (en) Formulations of Temozolomide for Parenteral Administration
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
WO2016005995A2 (en) Glycol free stable liquid compositions of bendamustine
WO2015071299A2 (en) Stable pharmaceutical compositions
JP2023516957A (ja) ダプトマイシン製剤
KR20140052122A (ko) 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US20060068008A1 (en) Lyophilized pharmaceutical compositions
CN108289840A (zh) 用于静脉内注射Danirixin的制剂
KR102226082B1 (ko) 멜팔란 플루펜아미드의 동결건조 제제
WO2005123137A2 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
HK1208351A1 (en) Method for producing a freeze-dried pharmaceutical composition containing mitomycin c
HK1208351B (en) Method for producing a freeze-dried pharmaceutical composition containing mitomycin c